CONSORT 2010 statement: Extension to randomised crossover trials

The BMJ

Volumn 366, Issue , 2019, Pages

  Dwan, Kerry ^a   Li, Tianjing ^b   Altman, Douglas G ^c   Elbourne, Diana ^d  

^a Review Production and Quality Unit   (United Kingdom)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL RESEARCH; METHODOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STUDY DESIGN; WORKFLOW; CROSSOVER PROCEDURE; PUBLISHING; STANDARDS; STATISTICAL ANALYSIS;

CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85070891088     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.l4378     Document Type: Article

References (64)

1. Page MJ, Higgins JP, Clayton G, Sterne JA, Hróbjartsson A, Savović J. Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. PLoS One 2016; 11: e0159267. doi: 10.1371/journal.pone.0159267
2. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12. doi: 10.1001/jama.1995.03520290060030
3. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332. doi: 10.1136/bmj.c332
4. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869. doi: 10.1136/bmj.c869
5. Shamseer L, Hopewell S, Altman DG, Moher D, Schulz KF. Update on the endorsement of CONSORT by high impact factor journals: a survey of journal "Instructions to Authors" in 2014. Trials 2016; 17: 301. doi: 10.1186/s13063-016-1408-z
6. Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ 2012; 345: e5661. doi: 10.1136/bmj. e5661
7. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012; 308: 2594-604. doi: 10.1001/jama.2012.87802
8. Vohra S, Shamseer L, Sampson M, et al, CENT Group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. BMJ 2015; 350: h1738. doi: 10.1136/bmj.h1738
9. Zwarenstein M, Treweek S, Gagnier JJ, et al, CONSORT Group, Pragmatic Trials in Healthcare (Practihc) Group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337: a2390. doi: 10.1136/bmj.a2390
10. Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ 2017; 357: j2835. doi: 10.1136/bmj.j2835
11. Zeng, L., L.A. Drye, T. Li, Characterizing current registration of phase 3 crossover trials on ClinicalTrials.gov. 2015. http://jhir.library.jhu.edu/handle/1774.2/38151.
12. Hui D, Zhukovsky DS, Bruera E. Which treatment is better? Ascertaining patient preferences with crossover randomized controlled trials. J Pain Symptom Manage 2015; 49: 625-31. doi: 10.1016/j.jpainsymman.2014.11.294
13. Cohlen BJ, te Velde ER, Looman CW, Eijckemans R, Habbema JD. Crossover or parallel design in infertility trials? The discussion continues. Fertil Steril 1998; 70: 40-5. doi: 10.1016/S0015-0282(98)00114-9
14. Makubate B, Senn S. Planning and analysis of cross-over trials in infertility. Stat Med 2010; 29: 3203-10. doi: 10.1002/sim.3981
15. Daya S. Differences between crossover and parallel study designs-debate?Fertil Steril 1999; 71: 771-3.
16. Jones B, Kenward MG. Design and Analysis of Cross-over Trials. 2nd edition ed. 2003, London: Chapman&Hall/CRC.
17. Senn S. Crossover-trials in Clinical Research. 2nd ed. Wiley, 2002. doi: 10.1002/0470854596.
18. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2012; 109: 276-81.
19. Gart JJ. An exact test for comparing matched proportions in cross-over designs. Biometrika 1969; 56: 75-80. doi: 10.1093/biomet/56.1.75
20. Mainland D. Elementary Medical Statistics. W.B. Saunders, 1963.
21. Freeman PR. The performance of the two-stage analysis of twotreatment, two-period crossover trials. Stat Med 1989; 8: 1421-32. doi: 10.1002/sim.4780081202
22. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005; 365: 1159-62. doi: 10.1016/S0140-6736(05)71879-1
23. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis, and presentation of crossover trials. Trials 2009; 10: 27. doi: 10.1186/1745-6215-10-27
24. Yu LM, Chan AW, Hopewell S, Deeks JJ, Altman DG. Reporting on covariate adjustment in randomised controlled trials before and after revision of the 2001 CONSORT statement: a literature review. Trials 2010; 11: 59. doi: 10.1186/1745-6215-11-59
25. Inrig JK, Califf RM, Tasneem A, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis 2014; 63: 771-80. doi: 10.1053/j.ajkd.2013.10.043
26. Odutayo A, Emdin CA, Hsiao AJ, et al. Association between trial registration and positive study findings: cross sectional study (Epidemiological Study of Randomized Trials-ESORT). BMJ 2017; 356: j917. doi: 10.1136/bmj.j917
27. Gewandter JS, McDermott MP, McKeown A, et al. Reporting of cross-over clinical trials of analgesic treatments for chronic pain: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review and recommendations. Pain 2016; 157: 2544-51. doi: 10.1097/j. pain.0000000000000673
28. Straube S, Werny B, Friede T. A systematic review identifies shortcomings in the reporting of crossover trials in chronic painful conditions. J Clin Epidemiol 2015; 68: 1496-503. doi: 10.1016/j. jclinepi.2015.04.006
29. Lathyris DN, Trikalinos TA, Ioannidis JP. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. Int J Epidemiol 2007; 36: 422-30. doi: 10.1093/ije/dym001
30. Li T, Yu T, Hawkins BS, Dickersin K. Design, analysis, and reporting of crossover trials for inclusion in a meta-analysis. PLoS One 2015; 10: e0133023. doi: 10.1371/journal.pone.0133023
31. Nolan SJ, Hambleton I, Dwan K. The use and reporting of the cross-over study design in clinical trials and systematic reviews: a systematic assessment. PLoS One 2016; 11: e0159014. doi: 10.1371/journal.pone.0159014
32. Ioannidis JP, Evans SJ, Gotzsche PC, et al. CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141: 781-8. doi: 10.7326/0003-4819-141-10-200411160-00009
33. Guo X, Kong X, Huang R, et al. Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: a randomized, crossover clinical trial. Invest Ophthalmol Vis Sci 2014; 55: 110-6. doi: 10.1167/iovs.13-13168
34. Johansson DP, Lee I, Risérus U, Langton M, Landberg R. Effects of unfermented and fermented whole grain rye crisp breads served as part of a standardized breakfast, on appetite and postprandial glucose and insulin responses: a randomized cross-over trial. PLoS One 2015; 10: e0122241. doi: 10.1371/journal.pone.0122241
35. Hopewell S, Clarke M, Moher D, et al, CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 2008; 371: 281-3. doi: 10.1016/S0140-6736(07)61835-2
36. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287: 719-25. doi: 10.1001/jama.287.6.719
37. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebocontrolled crossover trial. Lancet 2002; 360: 978-84. doi: 10.1016/S0140-6736(02)11081-6
38. Rubio-Aurioles E, Porst H, Kim ED, et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012; 9: 1418-29. doi: 10.1111/j.1743-6109.2012.02667.x
39. Escudier B, Porta C, Bono P, et al. Randomized, controlled, doubleblind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014; 32: 1412-8. doi: 10.1200/JCO.2013.50.8267
40. Konstas AG, Lake S, Economou AI, Kaltsos K, Jenkins JN, Stewart WC. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol 2006; 124: 1553-7. doi: 10.1001/archopht.124.11.1553
41. Gelderblom H, Wüstenberg T, McLean T, et al. Bupropion for the treatment of apathy in Huntington's disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS One 2017; 12: e0173872. doi: 10.1371/journal. pone.0173872
42. Julious SA, Campbell MJ, Altman DG. Estimating sample sizes for continuous, binary, and ordinal outcomes in paired comparisons: practical hints. J Biopharm Stat 1999; 9: 241-51. doi: 10.1081/BIP-100101174
43. Fogel RB, Rosario N, Aristizabal G, et al. Effect of montelukast or salmeterol added to inhaled fluticasone on exerciseinduced bronchoconstriction in children. Ann Allergy Asthma Immunol 2010; 104: 511-7. doi: 10.1016/j.anai.2009.12.011
44. Freemantle N, Satram-Hoang S, Tang ET, et al, DAPS Investigators. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012; 23: 317-26. doi: 10.1007/s00198-011-1780-1
45. Abell TL, Johnson WD, Kedar A, et al. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc 2011; 74: 496-503.e3.
46. Hill J, Bird HA, Fenn GC, Lee CE, Woodward M, Wright V. A double-blind crossover study to compare lysine acetyl salicylate (Aspergesic) with ibuprofen in the treatment of rheumatoid arthritis. J Clin Pharm Ther 1990; 15: 205-11. doi: 10.1111/j.1365-2710.1990.tb00376.x
47. Bonten TN, Snoep JD, Assendelft WJ, et al. Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial. Hypertension 2015; 65: 743-50. doi: 10.1161/HYPERTENSIONAHA.114.04980
48. Fleiss JL, Wallenstein S, Rosenfeld R. Adjusting for baseline measurements in the two-period crossover study: a cautionary note. Control Clin Trials 1985; 6: 192-7. doi: 10.1016/0197-2456(85)90002-9
49. Willan AR, Pater JL. Using baseline measurements in the twoperiod crossover clinical trial. Control Clin Trials 1986; 7: 282-9. doi: 10.1016/0197-2456(86)90036-X
50. Carpenter JR, Kenward MG. Sensitivity Analysis with Multiple Imputation. In: Molenberghs G, et al. eds. Handbook of Missing Data Methodology. CRC Press New York, 2015: 446.
51. Chen CY, Holbrook M, Duess MA, et al. Effect of almond consumption on vascular function in patients with coronary artery disease: a randomized, controlled, cross-over trial. Nutr J 2015; 14: 61. doi: 10.1186/s12937-015-0049-5
52. Marchetti E, Mummolo S, Di Mattia J, et al. Efficacy of essential oil mouthwash with and without alcohol: a 3-day plaque accumulation model. Trials 2011; 12: 262. doi: 10.1186/1745-6215-12-262
53. Markman JD, Frazer ME, Rast SA, et al. Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. Neurology 2015; 84: 265-72. doi: 10.1212/WNL.0000000000001168
54. Graff GR, Maguiness K, McNamara J, et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin Ther 2010; 32: 89-103. doi: 10.1016/j.clinthera.2010.01.012
55. Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014; 20: 398-406. doi: 10.1111/hae.12344
56. O'Connor DW, Eppingstall B, Taffe J, van der Ploeg ES. A randomized, controlled cross-over trial of dermally-applied lavender (Lavandula angustifolia) oil as a treatment of agitated behaviour in dementia. BMC Complement Altern Med 2013; 13: 315. doi: 10.1186/1472-6882-13-315
57. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002; 31: 140-9. doi: 10.1093/ije/31.1.140
58. Stedman MR, Curtin F, Elbourne DR, Kesselheim AS, Brookhart MA. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2011; 40: 1732-4. doi: 10.1093/ije/dyp345
59. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Stat Med 2002; 21: 2145-59. doi: 10.1002/sim.1206
60. Solomon DH, Garg R, Lu B, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken) 2014; 66: 1246-51. doi: 10.1002/acr.22285
61. Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA 2019; 321: 1610-20. doi: 10.1001/jama.2019.3087
62. Rietbergen C, Moerbeck M. The Design of Cluster Randomized Crossover Trials. J Educ Behav Stat 2011; 36: 472-90. doi: 10.3102/1076998610379136.
63. Arnup SJ, Forbes AB, Kahan BC, Morgan KE, McKenzie JE. Appropriate statistical methods were infrequently used in cluster-randomized crossover trials. J Clin Epidemiol 2016; 74: 40-50. doi: 10.1016/j.jclinepi.2015.11.013
64. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev 2012; 1: 60. doi: 10.1186/2046-4053-1-60